An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.

The U.S. faces an ongoing HIV epidemic, with women, particularly women of color, bearing a heavy burden. While there have ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...

Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

Utilizing syringe service programs to provide comprehensive PrEP care shows promise for encouraging more people who inject ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

Dr. Maya Green discusses HIV prevention, addressing racial disparities in healthcare, and the powerful impact of stigma on ...

There is almost complete halt of HIV Prevention interventions that were fully funded by PEPFAR. This includes DREAMS programme targeting vulnerable adolescent girls and young women, orphans and ...